Online Only Articles

The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies

Center of Cellular Therapy “G. Lanzani, USC Hematology, and Fondazione per la Ricerca Ospedale Maggiore, ASST Papa Giovanni XXIII, Bergamo, Italy
Center of Cellular Therapy “G. Lanzani, USC Hematology, and Fondazione per la Ricerca Ospedale Maggiore, ASST Papa Giovanni XXIII, Bergamo, Italy
Center of Cellular Therapy “G. Lanzani, USC Hematology, and Fondazione per la Ricerca Ospedale Maggiore, ASST Papa Giovanni XXIII, Bergamo, Italy
Vol. 102 No. 10 (2017): October, 2017 https://doi.org/10.3324/haematol.2017.169334